Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
VMF
0
API
0
FDF
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
1. (3s,11ar)-n-((2,6-difluoropyridin-3-yl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide
2. Apretude
3. Cabotegravir Extended-release Injectable Suspension
4. Cabotegravir Sodium
5. Gsk-1265744
6. Gsk-1265744a
7. Gsk-1265744b
8. Gsk1265744
9. Gsk1265744a
10. Gsk1265744b
11. Gsk744
12. N-((2,4-difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide
13. S-265744
14. S-265744b
15. Sodium (3s,11ar)-8-(((2,4-difluorophenyl)methyl)carbamoyl)-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo(3,2-a)pyrido(1,2-d)pyrazin-6-olate
16. Vocabria
1. 1051375-10-0
2. Gsk1265744
3. Gsk744
4. Gsk-1265744
5. Gsk1265744a
6. S-265744
7. Gsk744 Lap
8. Gsk-1265744a
9. Gsk744 La
10. Gsk 744
11. S/gsk1265744
12. Gsk 1265744
13. Cabotegravir (gsk744, Gsk1265744)
14. Gsk744 (s/gsk1265744)
15. Hmh0132z1q
16. (3s,11ar)-n-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
17. Cab
18. (3s,11ar)-n-((2,4-difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide
19. Unii-hmh0132z1q
20. Cabotegravir [usan:inn]
21. Cabotegravirum
22. 744 La
23. Cabotegravir [inn]
24. Cabotegravir [jan]
25. Cabotegravir [usan]
26. Schembl82803
27. Cabotegravir [who-dd]
28. Cabotegravir (jan/usan/inn)
29. Cabotegravir; Gsk1265744
30. Chembl2403238
31. Gtpl11386
32. Dtxsid50146982
33. Chebi:172944
34. Cabotegravir [orange Book]
35. Amy27899
36. Bcp08631
37. Ex-a2330
38. Bdbm50492496
39. Mfcd25976748
40. S7766
41. Zinc96927633
42. Cabenuva Component Cabotegravir
43. S/gsk-1265744
44. Cabenuva (cabotegravir + Rilpivirine)
45. Ccg-268708
46. Cs-5078
47. Db11751
48. Cabotegravir Component Of Cabenuva
49. Ncgc00386434-02
50. Ac-30895
51. As-61279
52. Hy-15592
53. S/gsk1265744; Gsk744
54. D10548
55. P14046
56. A902375
57. Q15411012
58. (3r,6s)-n-[(2,4-difluorophenyl)methyl]-10-hydroxy-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.0?,?]trideca-9,12-diene-12-carboxamide
59. (3r,6s)-n-[(2,4-difluorophenyl)methyl]-10-hydroxy-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.03,7]trideca-9,12-diene-12-carboxamide
60. (3s,11ar)-n-((2,6-difluoropyridin-3-yl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide
61. (3s,11ar)-n-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
62. (3s,11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
63. (3s,11ar)-n-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,11,11a-tetrahydrooxazolo[[?]]pyrido[[?]]pyrazine-8-carboxamide
64. (3s,11ar)-n-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
65. 1264720-72-0
66. N-((2,4-difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide
67. Oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide, N-((2,4-difluorophenyl)methyl)-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, (3s,11ar)-
Molecular Weight | 405.4 g/mol |
---|---|
Molecular Formula | C19H17F2N3O5 |
XLogP3 | 2.1 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 3 |
Exact Mass | 405.11362698 g/mol |
Monoisotopic Mass | 405.11362698 g/mol |
Topological Polar Surface Area | 99.2 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 814 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Oral cabotegravir is indicated in combination with rilpivirine for the short term treatment of HIV-1 in virologically suppressed adults with no history of treatment failure to assess tolerability of cabotegravir or who have missed an injected dose of cabotegravir. Intramuscular extended-release cabotegravir is indicated in combination with rilpivirine as a complete regimen for virologically suppressed adults with no history of treatment failure. The intramuscular form is meant to replace their current antiretroviral treatment.
Treatment of human immunodeficiency virus (HIV-1) infection
Vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class for:
- oral lead in to assess tolerability of Vocabria and rilpivirine prior to administration of long acting cabotegravir injection plus long acting rilpivirine injection.
- oral therapy for adults who will miss planned dosing with cabotegravir injection plus rilpivirine injection.
Vocabria injection is indicated, in combination with rilpivirine injection, for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class.
Treatment of human immunodeficiency virus (HIV-1) infection
Prevention of human immunodeficiency virus (HIV-1) infection
Cabotegravir is an inhibitor of HIV integrase, which reduces viral replication. It has a long duration of action as the oral tablet is given daily and the intramuscular suspension is given monthly. Patients should be counselled regarding the risk of hypersensitivity, hepatotoxicity, and depression.
HIV Integrase Inhibitors
Inhibitors of HIV INTEGRASE, an enzyme required for integration of viral DNA into cellular DNA. (See all compounds classified as HIV Integrase Inhibitors.)
J05AX
J - Antiinfectives for systemic use
J05 - Antivirals for systemic use
J05A - Direct acting antivirals
J05AJ - Integrase inhibitors
J05AJ04 - Cabotegravir
Absorption
Oral cabotegravir has a Tmax of 3 hours, reaches a Cmax of 8.0 g/mL, and has an AUC of 145 g\*h/mL. Intramuscular extended-release cabotegravir has a Tmax of 7 days, reaches a Cmax of 8.0 g/mL, and has an AUC of 1591 g\*h/mL.
Route of Elimination
An oral radiolabelled dose of cabotegravir is 58.5% recovered in the feces and 26.8% recovered in the urine.
Volume of Distribution
Data regarding the volume of distribution of cabotegravir is not readily available.
Clearance
Data regarding the clearance of cabotegravir is not readily available. Clearance in dogs was 0.34 mL/min/kg and in cynomolgus monkeys was 0.32 mL/min/kg.
Cabotegravir is O-glucuronidated to the M1 and M2 metabolites, with 67% of glucuronidation performed by UGT1A1, and 33% by UGT1A9.
The mean half life of oral cabotegravir is 41 hours. The mean half life of intramuscular extended-release cabotegravir is 5.6-11.5 weeks.
Cabotegravir binds to the active site of HIV integrase, preventing strand transfer of the viral genome into the host genome, and preventing replication of the virus.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37939
Submission : 2023-03-20
Status : Active
Type : II
NDC Package Code : 53104-7740
Start Marketing Date : 2023-11-16
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
Details:
Apretude (cabotegravir) is an HIV-1 integrase strand transfer inhibitor indicated in at-risk adults and adolescents for PrEP to reduce risk of sexually acquired HIV-1 infection.
Lead Product(s): Cabotegravir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Apretude
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2024
Lead Product(s) : Cabotegravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ViiV Announces Health Canada Approval for APRETUDE for HIV Pre-Exposure Prophylaxis
Details : Apretude (cabotegravir) is an HIV-1 integrase strand transfer inhibitor indicated in at-risk adults and adolescents for PrEP to reduce risk of sexually acquired HIV-1 infection.
Brand Name : Apretude
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 13, 2024
Details:
The UK MHRA approved two new formulations of cabotegravir (Apretude 30 mg & Apretude 600 mg) for preventing sexually transmitted HIV-1 infection in adults and adolescents.
Lead Product(s): Cabotegravir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Apretude
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2024
Lead Product(s) : Cabotegravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
UK MHRA Approves ViiV’s Cabotegravir Formulations for Preventing HIV-1 Infection
Details : The UK MHRA approved two new formulations of cabotegravir (Apretude 30 mg & Apretude 600 mg) for preventing sexually transmitted HIV-1 infection in adults and adolescents.
Brand Name : Apretude
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 04, 2024
Details:
Edurant (rilpivirine) is an NNRTI for HIV-1 treatment, indicated for use with other antiretroviral agents in managing HIV-1 infection.
Lead Product(s): Rilpivirine,Cabotegravir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Edurant
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2024
Lead Product(s) : Rilpivirine,Cabotegravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves EDURANT® PED for Certain Pediatric Patients Living with HIV-1
Details : Edurant (rilpivirine) is an NNRTI for HIV-1 treatment, indicated for use with other antiretroviral agents in managing HIV-1 infection.
Brand Name : Edurant
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 19, 2024
Details:
Cabenuva is a combination of cabotegravir, which inhibits HIV integrase by blocking retroviral DNA integration, and rilpivirine, which inhibits HIV-1 reverse transcriptase.
Lead Product(s): Cabotegravir,Rilpivirine
Therapeutic Area: Infections and Infectious Diseases Brand Name: Cabenuva
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Lead Product(s) : Cabotegravir,Rilpivirine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ViiV Reports Superior Efficacy Of Cabenuva Injectable HIV Treatment
Details : Cabenuva is a combination of cabotegravir, which inhibits HIV integrase by blocking retroviral DNA integration, and rilpivirine, which inhibits HIV-1 reverse transcriptase.
Brand Name : Cabenuva
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 06, 2024
Details:
Apretude (cabotegravir) is an integrase strand transfer inhibitor, long acting injection, which is being evaluated for the treatment of HIV-1 infection.
Lead Product(s): Cabotegravir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Apretude
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
Lead Product(s) : Cabotegravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ViiV Presents Phase I Findings of Cabotegravir Long-acting Injectable for HIV Prevention
Details : Apretude (cabotegravir) is an integrase strand transfer inhibitor, long acting injection, which is being evaluated for the treatment of HIV-1 infection.
Brand Name : Apretude
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 04, 2024
Details:
Cabenuva (cabotegravir + rilpivirine) is combination of HIV-1 integrase strand transfer inhibitor & RT inhibitor, being evaluated HIV-1 infection in adults.
Lead Product(s): Cabotegravir,Rilpivirine
Therapeutic Area: Infections and Infectious Diseases Brand Name: Cabenuva
Study Phase: Phase II/ Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2024
Lead Product(s) : Cabotegravir,Rilpivirine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LATITUDE Phase III Data Shows Cabenuva Superior to Daily Therapy for HIV
Details : Cabenuva (cabotegravir + rilpivirine) is combination of HIV-1 integrase strand transfer inhibitor & RT inhibitor, being evaluated HIV-1 infection in adults.
Brand Name : Cabenuva
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 21, 2024
Details:
Apretude (cabotegravir) is an HIV-1 integrase strand transfer inhibitor indicated in at-risk adults and adolescents for PrEP to reduce risk of sexually acquired HIV-1 infection.
Lead Product(s): Cabotegravir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Apretude
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2024
Lead Product(s) : Cabotegravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Health Canada Grants Priority Review for ViiV's Cabotegravir for HIV Prevention
Details : Apretude (cabotegravir) is an HIV-1 integrase strand transfer inhibitor indicated in at-risk adults and adolescents for PrEP to reduce risk of sexually acquired HIV-1 infection.
Brand Name : Apretude
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 10, 2024
Details:
Vocabria (cabotegravir injection) is an integrase strand transfer inhibitor and used in combination with the Janssen Pharmaceutical Companies of Johnson & Johnson's Rekambys (rilpivirine long-acting injection) for the treatment of HIV-1 infection.
Lead Product(s): Cabotegravir,Rilpivirine
Therapeutic Area: Infections and Infectious Diseases Brand Name: Vocabria
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2023
Lead Product(s) : Cabotegravir,Rilpivirine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ViiV Healthcare Receives Approval from China’s National Medical Products Administration (NMPA) f...
Details : Vocabria (cabotegravir injection) is an integrase strand transfer inhibitor and used in combination with the Janssen Pharmaceutical Companies of Johnson & Johnson's Rekambys (rilpivirine long-acting injection) for the treatment of HIV-1 infection.
Brand Name : Vocabria
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 26, 2023
Details:
Apretude (cabotegravir) long-acting for PrEP is an integrase strand transfer inhibitor (INSTI), which is indicated for the treatment of sexually acquired HIV-1 infection.
Lead Product(s): Cabotegravir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Apretude
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: ViiV Healthcare
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2023
Lead Product(s) : Cabotegravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : ViiV Healthcare
Deal Size : Not Applicable
Deal Type : Not Applicable
European Commission authorises ViiV Healthcare’s Apretude (cabotegravir long-acting and tablets)...
Details : Apretude (cabotegravir) long-acting for PrEP is an integrase strand transfer inhibitor (INSTI), which is indicated for the treatment of sexually acquired HIV-1 infection.
Brand Name : Apretude
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 19, 2023
Details:
CAB LA (cabotegravir) long-acting for PrEP is an integrase strand transfer inhibitor (INSTI). INSTIs, like cabotegravir extended-release injectable suspension, inhibit HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells.
Lead Product(s): Cabotegravir
Therapeutic Area: Infections and Infectious Diseases Brand Name: CAB LA
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2023
Lead Product(s) : Cabotegravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ViiV Healthcare’s Cabotegravir for HIV Prevention Receives Positive CHMP Opinion From European M...
Details : CAB LA (cabotegravir) long-acting for PrEP is an integrase strand transfer inhibitor (INSTI). INSTIs, like cabotegravir extended-release injectable suspension, inhibit HIV replication by preventing the viral DNA from integrating into the genetic material...
Brand Name : CAB LA
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 24, 2023
RLD : Yes
TE Code :
Brand Name : CABENUVA KIT
Dosage Form : SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
Dosage Strength : 400MG/2ML (200MG/ML);600MG/2ML (300MG/ML)
Approval Date : 2021-01-21
Application Number : 212888
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : CABENUVA KIT
Dosage Form : SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
Dosage Strength : 600MG/3ML (200MG/ML);900MG/3ML (300MG/ML)
Approval Date : 2021-01-21
Application Number : 212888
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : APRETUDE
Dosage Form : SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
Dosage Strength : 600MG/3ML (200MG/ML)
Approval Date : 2021-12-20
Application Number : 215499
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
Global Sales Information
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?